AstraZeneca's Enhertu Wins EU Tumour-Agnostic Approval for HER2-Positive Cancers

What Changed

AstraZeneca has received European Union regulatory approval for Enhertu (trastuzumab deruxtecan) as a tumour-agnostic treatment for HER2-positive solid tumours. A tumour-agnostic designation is a relatively new and significant regulatory category: it allows a drug to be prescribed for any cancer that carries a specific biomarker (in this case, HER2 positivity), regardless of where in the body the tumour originated.

Enhertu is an antibody-drug conjugate developed through AstraZeneca's oncology partnership with Japan's Daiichi Sankyo. Under their collaboration agreement, the two companies co-develop and co-commercialise Enhertu globally, with AstraZeneca receiving a share of net sales.

Why Tumour-Agnostic Approval Is a Step Change

Previous Enhertu approvals were cancer-specific: the drug had been cleared for HER2-positive and HER2-low breast cancer, as well as HER2-positive gastric cancer. These are substantial markets, but they are limited to patients with those specific tumour types.

A tumour-agnostic EU approval changes the commercial calculus fundamentally. HER2 overexpression is found across a wide range of solid tumours beyond breast and stomach -- including lung, colorectal, cervical, biliary tract and urothelial cancers. The number of patients potentially eligible for Enhertu treatment expands considerably, as oncologists can now consider the drug for any patient whose tumour tests HER2-positive, regardless of the primary cancer site.

This approval also sets a precedent that may support similar applications in other major markets, including a broadened US label.

AstraZeneca: Which Stocks and Why

For AstraZeneca, Enhertu has become one of the most commercially important assets in its oncology portfolio, which alongside other ADCs and immunotherapy agents forms the core of the company's growth strategy. The tumour-agnostic approval adds a new dimension to the drug's revenue trajectory at a time when AstraZeneca has committed to ambitious long-term revenue targets.

Investors should note that the commercial benefit to AstraZeneca depends on the EU reimbursement decisions by individual member states, which take place after regulatory approval and can significantly affect patient access and actual prescribing volumes. France, Germany and other major European markets typically negotiate prices that determine the real-world uptake pace.

What to Watch

The key near-term catalysts are the rollout of reimbursement agreements across major EU markets, prescribing volume data in the first quarters post-approval, and any update from AstraZeneca on revised Enhertu revenue guidance to reflect the expanded indication. Investors should also watch for parallel regulatory submissions in the US and Japan based on similar clinical data.